Stay updated on ABP798 vs Rituximab in NHL: Clinical Trial
Sign up to get notified when there's something new on the ABP798 vs Rituximab in NHL: Clinical Trial page.

Latest updates to the ABP798 vs Rituximab in NHL: Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check51 days agoChange DetectedRevision: v3.4.2 was added, replacing v3.4.1, indicating a minor update. This does not modify study content, eligibility criteria, or results; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check58 days agoChange DetectedThe IPD Sharing section now lists Revision: v3.4.1, replacing v3.4.0, indicating a document version update.SummaryDifference0.0%

- Check72 days agoChange DetectedShow glossary option added; Last Update Submitted that Met QC Criteria label appears with capitalization changes and a new Revision: v3.4.0 notice. These are administrative updates and do not affect study content, eligibility, or locations; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check79 days agoChange DetectedRevision history updated to show Revision: v3.3.4 and removed Revision: v3.3.3. This update does not affect the study content, eligibility criteria, or results.SummaryDifference0.0%

Stay in the know with updates to ABP798 vs Rituximab in NHL: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABP798 vs Rituximab in NHL: Clinical Trial page.